nach oben

CNS Drugs

Erschienen in:

01.01.2010 | Adis Spotlight

Spotlight on Atomoxetine in Attention-Deficit Hyperactivity Disorder in Children and Adolescentsy

verfasst von: Karly P. Garnock-Jones, Gillian M. Keating

Erschienen in: CNS Drugs | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Atomoxetine (Strattera®) is a selective noradrenaline (norepinephrine) reuptake inhibitor that is not classified as a stimulant, and is indicated for use in patients with attention-deficit hyperactivity disorder (ADHD).

Atomoxetine is effective and generally well tolerated. It is significantly more effective than placebo and standard current therapy and does not differ significantly from, or is noninferior to, immediate-release methylphenidate; however, it is significantly less effective than the extended-release methylphenidate formulation OROS® methylphenidate (hereafter referred to as osmotically released methylphenidate) and extended-release mixed amfetamine salts.

Atomoxetine can be administered either as a single daily dose or split into two evenly divided doses, has a negligible risk of abuse or misuse and is not a controlled substance in the US. Atomoxetine is particularly useful for patients at risk of substance abuse, as well as those who have co-morbid anxiety or tics, or who do not wish to take a controlled substance. Thus, atomoxetine is a useful option in the treatment of ADHD in children and adolescents.

Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Pediatr Drugs 2009; 11(3): 203–26CrossRef

Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child 2005 Feb; 90Suppl. 1: i26–9PubMedCrossRef

Ledbetter M. Atomoxetine: a novel treatment for child and adult ADHD. Neuropsych Dis Treat 2006; 2(4): 455–66CrossRef

Bolden-Watson C, Richelson E. Blockade of newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52(12): 1023–9PubMedCrossRef

Wong DT, Threlkeld PG, Best KL, et al. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther 1982; 222(1): 61–5PubMed

Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002 Nov; 27(5): 699–711PubMedCrossRef

Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl) 1994; 114(4): 559–65CrossRef

Zerbe RL, Rowe H, Enas GG, et al. Clinical pharmacology of tomoxetine, a potential antidepressant. J Pharmacol Exp Ther 1985; 232(1): 139–43PubMed

Gehlert DR, Schober DA, Gackenheimer SL. Comparison of (R)-[³H]tomoxetine and (R/S)-[³H]nisoxetine binding in rat brain. J Neurochem 1995; 64(6): 2792–800PubMedCrossRef

10.

Gehlert DR, Gackenheimer SL, Robertson DW. Localization of rat brain binding sites for [³H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites. Neurosci Lett 1993; 157(2): 203–6PubMedCrossRef

11.

Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26(10): 729–40PubMedCrossRef

12.

Spencer TJ, Kratochvil CJ, Sangal RB, et al. Effects of atomoxetine on growth in children with attention-deficit/ hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol 2007 Oct; 17(5): 689–700PubMedCrossRef

13.

Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002 Jul 1; 67(2): 149–56PubMedCrossRef

14.

Lile JA, Stoops WW, Durell TM, et al. Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans. Exp Clin Psychopharmacol 2006 May; 14(2): 136–47PubMedCrossRef

15.

Sangal RB, Owens J, Allen AJ, et al. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep 2006 Dec 1; 29(12): 1573–85PubMed

16.

Witcher JW, Long A, Smith B, et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2003 Spring; 13(1): 53–63PubMedCrossRef

17.

Eli Lilly and Company. Atomoxetine (Strattera™) prescribing information [online]. Available from URL: http://pi.lilly.com/us/strattera-pi.pdf [Accessed 2009 Feb 9]

18.

Belle DJ, Ernest CS, Sauer J-M, et al. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 2002 Nov; 42(11): 1219–27PubMedCrossRef

19.

Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001 Nov; 108(5): E83–91PubMedCrossRef

20.

Eli Lilly. Clinical study summary: study B4Z-MC-LYAC. A phase 3 randomized, double-blind, placebo-controlled efficacy and safety comparison of fixed-dose ranges (mg/kg/day) of tomoxetine with placebo in child and adolescent outpatients with ADHD, aged 8 to 18 years. [online]. Available from URL: http://www.clinicalstudyresults.org/documents/company-study_163_0.pdf [Accessed 2009 Feb 9]

21.

Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002 Nov; 159(11): 1896–901PubMedCrossRef

22.

Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002 Dec; 63(12): 1140–7PubMedCrossRef

23.

Gau SS, Huang YS, Soong WT, et al. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007 Aug; 17(4): 447–60PubMedCrossRef

24.

Brown RT, Perwien A, Faries DE, et al. Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning. Clin Pediatr (Phila) 2006 Nov; 45(9): 819–27CrossRef

25.

Weiss M, Tannock R, Kratochvil C, et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005 Jul; 44(7): 647–55PubMedCrossRef

26.

Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/ hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004 Jul; 114(1): e1–8PubMedCrossRef

27.

Michelson D, Buitelaar JK, Danckaerts M, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004 Jul; 43(7): 896–904PubMedCrossRef

28.

Buitelaar JK, Michelson D, Danckaerts M, et al. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry 2007 Mar 1; 61(5): 694–9PubMedCrossRef

29.

Wernicke JF, Adler L, Spencer T, et al. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/ hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol 2004 Feb; 24(1): 30–5PubMedCrossRef

30.

Wilens TE, Kratochvil C, Newcorn JH, et al. Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child Adolesc Psychiatry 2006 Feb; 45(2): 149–57PubMedCrossRef

31.

Escobar R, Montoya A, Polavieja P, et al. Evaluation of patients’ and parents’ quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/ hyperactivty disorder. J Child Adolesc Psychopharmacol 2009; 19(3): 253–63PubMedCrossRef

32.

Svanborg P, Thernlund G, Gustafsson PA, et al. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naive Swedish children and adolescents. Eur Child Adolesc Psychiatry 2009 Apr; 18(4): 240–9PubMedCrossRef

33.

Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002 Jul; 41(7): 776–84PubMedCrossRef

34.

Wang Y, Zheng Y, Du Y, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust NZ J Psychiatry 2007 Mar; 41(3): 222–30CrossRef

35.

Prasad S, Harpin V, Poole L, et al. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin 2007 Feb; 23(2): 379–94PubMedCrossRef

36.

Kemner JE, Starr HL, Ciccone PE, et al. Outcomes of OROS® methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther 2005 Sep 31; 22(5): 498–512PubMedCrossRef

37.

Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008; 165(6): 721–30PubMedCrossRef

38.

Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005 Aug; 9(1): 275–89PubMedCrossRef

39.

Bangs ME, Hazell P, Danckaerts M, et al. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics 2008 Feb; 121(2): e314–20PubMedCrossRef

40.

Bangs ME, Emslie GJ, Spencer TJ, et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit/ hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol 2007 Aug; 17(4): 407–20PubMedCrossRef

41.

Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyper-activity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 2007 Sep; 46(9): 1119–27PubMedCrossRef

42.

Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006 Oct; 45(10): 1196–205PubMedCrossRef

43.

Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005 Dec 27; 65(12): 1941–9PubMedCrossRef

44.

Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 2005 Sep; 44(9): 915–24PubMedCrossRef

45.

Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Metaanalysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008 Feb; 47(2): 209–18PubMedCrossRef

46.

Bangs ME, Jin L, Zhang S, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf 2008; 31(4): 345–54PubMedCrossRef

47.

Cottrell S, Tilden D, Robinson P, et al. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Value Health 2008 May 30; 11(3): 376–88PubMedCrossRef

48.

Tilden D, Richardson R, Nyhus K, et al. A modelled economic evaluation of atomoxetine (Strattera) for the treatment of three patient groups with attention deficit hyperactivity disorder [abstract no. PMH5]. Value Health 2005 Dec 6; 8: A197. Plus poster presented at the International Society for Pharmacoeconomics and Outcomes Research Eighth Annual European Congress; 2005 Nov 6–8; FlorenceCrossRef

49.

Laing A, Cottrell S, Robinson P, et al. A modelled economic evaluation comparing atomoxetine with current therapies for the treatment of children with attention deficit/hyperactivity disorder in The Netherlands [abstract no. PMH10]. Value Health 2005 Dec 6; 8: A198. Plus poster presented at the International Society for Pharmacoeconomics and Outcomes Research Eighth Annual European Congress; 2005 Nov 6–8; FlorenceCrossRef

50.

Diamantopoulos A, Lorenzo M, Happich M, et al. A cost-utilty analysis of atomoxetine against current stimulant therapies for the treatment of children with attention deficit/hyperactivity disorder in Germany [abstract no. PMH36]. Value Health 2007 Nov 31; 10: A298. Plus poster presented at the International Society for Pharmacoeconomics and Outcomes Research Tenth Annual European Congress; 2007 Oct 20–23; DublinCrossRef

Titel: Spotlight on Atomoxetine in Attention-Deficit Hyperactivity Disorder in Children and Adolescentsy
verfasst von: Karly P. Garnock-Jones
Gillian M. Keating
Publikationsdatum: 01.01.2010
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 1/2010
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/11203670-000000000-00000

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Spotlight on Atomoxetine in Attention-Deficit Hyperactivity Disorder in Children and Adolescentsy

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Simple Kortisontherapie stoppt primär progrediente Aphasie

Impostor-Syndrom häufig bei Hyperhidrose zu finden

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Progress in Defining Optimal Treatment Outcome in Schizophrenia

Blonanserin

Factors Associated with Serious Adverse Reactions to Cholinesterase Inhibitors

Role of Antiepileptic Drugs as Preventive Agents for Migraine

Safety Reporting and Adverse-Event Profile of Mirtazapine Described in Randomized Controlled Trials in Comparison with Other Classes of Antidepressants in the Acute-Phase Treatment of Adults with Depression

Role of Brain-Derived Neurotrophic Factor in the Aetiology of Depression

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Simple Kortisontherapie stoppt primär progrediente Aphasie

Impostor-Syndrom häufig bei Hyperhidrose zu finden

Update Neurologie